Cost-effectiveness of a technology-supported multimodal prehabilitation program in moderate-to-high risk patients undergoing lung cancer resection: randomized controlled trial protocol

BMC Health Serv Res. 2020 Mar 12;20(1):207. doi: 10.1186/s12913-020-05078-9.

Abstract

Background: Multimodal prehabilitation is a preoperative intervention with the objective to enhance cancer patients' functional status which has been showed to reduce both postoperative morbidity and hospital length of stay in digestive oncologic surgery. However, in lung cancer surgery patients further studies with higher methodological quality are needed to clarify the benefits of prehabilitation. The main aim of the current protocol is to evaluate the cost-effectiveness of a multimodal prehabilitation program supported by information and communication technologies in moderate-to-high risk lung cancer patients undergoing thoracic surgery.

Methods: A Quadruple Aim approach will be adopted, assessing the prehabilitation program at the following levels: i) Patients' and professionals' experience outcomes (by means of standardized questionnaires, focus groups and structured interviews); ii) Population health-based outcomes (e.g. hospital length of stay, number and severity of postoperative complications, peak oxygen uptake and levels of systemic inflammation); and, iii) Healthcare costs.

Discussion: This study protocol should contribute not only to increase the scientific basis on prehabilitation but also to detect the main factors modulating service adoption.

Trial registration: NCT04052100 (August 9, 2019).

Keywords: Cognitive behavioral therapy; Exercise training; Nutritional optimization; Physical activity; Postoperative morbidity; Prehabilitation; Smoking cessation.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Clinical Protocols
  • Combined Modality Therapy
  • Cost-Benefit Analysis
  • Humans
  • Information Technology
  • Lung Neoplasms / surgery*
  • Preoperative Care / economics*
  • Preoperative Care / methods*
  • Risk Assessment

Associated data

  • ClinicalTrials.gov/NCT04052100